Ing. L.G.M. van Baarsen PhD publications

foto

Publications Ing. L.G.M. van Baarsen PhD

Position
Associate professor (UHD)
Main activities
Research
Specialisation
Genomics; Immunology; Translational Research; Celbiology; Rheumatology; Stromal cells
Focus of research

To ultimately cure or prevent rheumatoid arthritis, it is critical to understand the earliest changes in the immune system that cause RA. Starting from a genome-wide expression profiling approach, this research will delineate the role of stromal cells in bone marrow, lymph node and synovial tissue in arthritis development. Results from these studies will provide innovative drug targets for preventive intervention in pre-clinical RA and identify the immunological processes that initiate RA and possibly other related chronic inflammatory diseases. In addition, molecular profiling of biomaterials is used to identify biomarkers for diagnosis, prognosis and treatment response.

2018

  • Hähnlein JS. Human lymph node stromal cells and their role in rheumatoid arthritis. S.l.: s.n.; 2018. 196p. ISBN 9789463752060 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Tak PP, Geijtenbeek TBH; copromotor(s): van Baarsen EGM)
  • Hähnlein JS, Nadafi R, de Jong T, Ramwadhdoebe TH, Semmelink JF, Maijer KI, Zijlstra IA, Maas M, Gerlag DM, Geijtenbeek TBH, Tak PP, Mebius RE, van Baarsen LGM, Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis. ARTHRITIS RES THER 2018;20 (1):35 [PubMed]
  • Hähnlein JS, Ramwadhdoebe TH, Semmelink JF, Choi IY, Berger FH, Maas M, Gerlag DM, Tak PP, Geijtenbeek TBH, van Baarsen LGM, Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering. SCI REP-UK 2018;8 (1):1736 [PubMed]

2017

  • Rodríguez-Carrio J, Hähnlein JS, Ramwadhdoebe TH, Semmelink JF, Choi IY, van Lienden KP, Maas M, Gerlag DM, Tak PP, Geijtenbeek TBH, van Baarsen LGM, Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis. ARTHRITIS RHEUMATOL 2017;69 (1):70-76 [PubMed]

2016

  • Angiolilli C, Grabiec AM, Ferguson BS, Ospelt C, Malvar Fernandez B, van Es IE, van Baarsen LGM, Gay S, McKinsey TA, Tak PP, Baeten DL, Reedquist KA, Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. ANN RHEUM DIS 2016;75 (2):430-438 [PubMed]
  • Ramwadhdoebe TH, Hähnlein J, Maijer KI, van Boven LJ, Gerlag DM, Tak PP, van Baarsen LGM, Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis. EUR J IMMUNOL 2016;46 (12):2812-2821 [PubMed]
  • Ramwadhdoebe TH, Hähnlein J, van Kuijk BJ, Choi IY, van Boven LJ, Gerlag DM, Tak PP, van Baarsen LG, Human lymph-node CD8(+) T cells display an altered phenotype during systemic autoimmunity. CLIN TRANSL IMMUNOL 2016;5 (4):UNSP e67 [PubMed]

2015

  • de Hair MJH, Leclerc P, Newsum EC, Maijer KI, van de Sande MGH, Ramwadhdoebe TH, van Schaardenburg D, van Baarsen LGM, Korotkova M, Gerlag DM, Tak PP, Jakobsson PJ, Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients. PLOS ONE 2015;10 (7):e0133669 [PubMed]
  • Grabiec AM, Angiolilli C, Hartkamp LM, van Baarsen LGM, Tak PP, Reedquist KA, JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis. ANN RHEUM DIS 2015;74 (9):1763-1771 [PubMed]
  • Noort AR, van Zoest KPM, van Baarsen LG, Maracle CX, Helder B, Papazian N, Romera-Hernandez M, Tak PP, Cupedo T, Tas SW, Tertiary Lymphoid Structures in Rheumatoid Arthritis: NF-κB-Inducing Kinase-Positive Endothelial Cells as Central Players. AM J PATHOL 2015;185 (7):1935-1943 [PubMed]

2014

  • Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, van Baarsen LGM, Ponchel F, Gene expression analysis in RA: towards personalized medicine. PHARMACOGENOMICS J 2014;14 (2):93-106 [PubMed]
  • de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LGM, Tak PP, Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. ARTHRITIS RHEUMATOL 2014;66 (3):513-522 [PubMed]
  • de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, van der Leij C, Maas M, Hansson M, Klareskog L, Landewé R, Serre G, van Schaardenburg D, Gerlag DM, van Baarsen LGM, Tak PP, Reply. ARTHRITIS RHEUMATOL 2014;66 (6):1683-1684 [PubMed]
  • van Baarsen LGM, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, Gerlag DM, Tak PP, Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. ARTHRITIS RES THER 2014;16 (4):426 [PubMed]

2013

  • de Hair MJH. Clinical studies and tissues analyses in the earliest phases of rheumatoid arthritis: in search of the transition from being at risk to having clinically apparent disease. s.l.: s.n.; 2013. 174p. ISBN 9789461822536 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Tak PP; copromotor(s): van Baarsen EGM)
  • de Hair MJH, Landewé RBM, van de Sande MGH, van Schaardenburg D, van Baarsen LGM, Gerlag DM, Tak PP, Smoking and overweight determine the likelihood of developing rheumatoid arthritis. ANN RHEUM DIS 2013;72 (10):1654-1658 [PubMed]
  • van Baarsen LGM, de Hair MJH, Ramwadhdoebe TH, Zijlstra IJAJ, Maas M, Gerlag DM, Tak PP, The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. ANN RHEUM DIS 2013;72 (8):1420-1424 [PubMed]

2012

  • de Launay D, van de Sande MGH, de Hair MJH, Grabiec AM, van de Sande GPM, Lehmann KA, Wijbrandts CA, van Baarsen LGM, Gerlag DM, Tak PP, Reedquist KA, Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. ANN RHEUM DIS 2012;71 (3):415-423 [PubMed]
  • Gerlag DM, Raza K, van Baarsen LGM, Brouwer E, Buckley CD, Burmester GR, Gabay C, Catrina AI, Cope AP, Cornelis F, Dahlqvist SR, Emery P, Eyre S, Finckh A, Gay S, Hazes JM, van der Helm-van Mil A, Huizinga TWJ, Klareskog L, Kvien TK, Lewis C, Machold KP, Rönnelid J, van Schaardenburg D, Schett G, Smolen JS, Thomas S, Worthington J, Tak PP, EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. ANN RHEUM DIS 2012;71 (5):638-641 [PubMed]

2011

  • Corr M, Boyle DL, Ronacher LM, Lew BR, van Baarsen LG, Tak PP, Firestein GS, Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. ANN RHEUM DIS 2011;70 (5):858-863 [PubMed]
  • van Baarsen LGM, Lodde BM, Tak PP, Kan therapie op maat realiteit worden?. NED TIJDSCHR GENEESKD 2011;155 (30-31):A3569 [PubMed]
  • van de Sande MGH, Gerlag DM, Lodde BM, van Baarsen LGM, Alivernini S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP, Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. ANN RHEUM DIS 2011;70 (3):423-427 [PubMed]

2010

  • Cantaert T, Baeten D, Tak PP, van Baarsen LGM, Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. ARTHRITIS RES THER 2010;12 (5):219 [PubMed]
  • Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw TK, Verweij CL, Tak PP, Baeten DL, Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. RHEUMATOLOGY 2010;49 (1):156-166 [PubMed]
  • Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP, The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis. PLOS ONE 2010;5 (6):e11310 [PubMed]
  • Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP, Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. ARTHRITIS RHEUM-US 2010;62 (12):3607-3614 [PubMed]
  • van Baarsen LGM, Reumatoïde artritis: naar planning van behandeling op individueel niveau?. NED TIJDSCHR REUMATOL 2010;2010 (1):11-14
  • van Baarsen LGM, Bos WH, Rustenburg F, van der Pouw Kraan TCTM, Wolbink GJJ, Dijkmans BAC, van Schaardenburg D, Verweij CL, Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. ARTHRITIS RHEUM-US 2010;62 (3):694-704 [PubMed]
  • van Baarsen LGM, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TCTM, Dijkmans BAC, Tak PP, Verweij CL, Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. GENES IMMUN 2010;11 (8):622-629 [PubMed]
  • van Baarsen LGM, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TCTM, Baeten DL, Dijkmans BAC, Tak PP, Verweij CL, Regulation of interferon response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. ARTHRITIS RES THER 2010;12 (1):R11 [PubMed]
  • van Baarsen LGM, Wijbrandts CA, Timmer TCG, van der Pouw Kraan TCTM, Tak PP, Verweij CL, Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. ARTHRITIS RHEUM-US 2010;62 (6):1602-1607 [PubMed]

2009

  • Bos CL, van Baarsen LGM, Timmer TCG, Overbeek MJ, Basoski NM, Rustenburg F, Baggen JMC, Thiesen HJ, Dijkmans BAC, van der Pouw Kraan TCTM, Voskuyl AE, Verweij CL, Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. GENES IMMUN 2009;10 (3):210-218 [PubMed]
  • van Baarsen LGM, Bos CL, van der Pouw Kraan TCTM, Verweij CL, Transcription profiling of rheumatic diseases. ARTHRITIS RES THER 2009;11 (1):207 [PubMed]
  • Vosslamber S, van Baarsen LGM, Verweij CL, Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. PHARMACOGENOMICS 2009;10 (1):97-108 [PubMed]

2008

  • van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, Killestein J, van der Pouw Kraan TCTM, Polman CH, Verweij CL, Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLOS ONE 2008;3 (4):e1927 [PubMed]
  • van der Pouw Kraan TCTM, van Baarsen LGM, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, Dijkmans BAC, Tak PP, Verweij CL, Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. GENES IMMUN 2008;9 (1):16-22 [PubMed]
  • van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP, Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. ANN RHEUM DIS 2008;67 (4):563-566 [PubMed]

2007

  • Lebre MC, van der Aar AMG, van Baarsen L, van Capel TMM, Schuitemaker JHN, Kapsenberg ML, de Jong EC, Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J INVEST DERMATOL 2007;127 (2):331-341 [PubMed]
  • van der Pouw Kraan TCTM, van Baarsen LGM, Rustenburg F, Baltus B, Fero M, Verweij CL, Gene expression profiling in rheumatology. METHODS MOL MED 2007;136:305-327 [PubMed]
  • van der Pouw Kraan TCTM, Wijbrandts CA, van Baarsen LGM, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BAC, Tak PP, Verweij CL, Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. ANN RHEUM DIS 2007;66 (8):1008-1014 [PubMed]

2006

  • van Baarsen LGM, van der Pouw Kraan TCTM, Kragt JJ, Baggen JMC, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL, A subtype of multiple sclerosis defined by an activated immune defense program. GENES IMMUN 2006;7 (6):522-531 [PubMed]
  • van Baarsen LGM, van der Pouw-Kraan TCTM, Verweij CL, A genomic view of subtypes in rheumatoid arthritis: towards personalized medicine. FUTURE RHEUMATOL 2006;1 (3):311-322

2005

  • Kasperkovitz PV, Timmer TCG, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LGM, Baltus B, Huizinga TWJ, Pieterman E, Fero M, Firestein GS, van der Pouw Kraan TCTM, Verweij CL, Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity - Evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. ARTHRITIS RHEUM-US 2005;52 (2):430-441 [PubMed]

2003

  • Bayley JP, van Rietschoten JGI, Bakker AM, van Baarsen L, Kaijzel EL, Wierenga EA, van der Pouw Kraan TCTM, Huizinga TWJ, Verweij CL, Allele-specific expression of the IL-1 alpha gene in human CD4+ T cell clones. J IMMUNOL 2003;171 (5):2349-2353 [PubMed]